French pharma giant Sanofi-Aventis has been denied a request to block sales of a generic version of its Lovenox blood thinner by a US district court.
The US District for Columbia refused to issue a preliminary injunction to block the generic, marketed by Novartis AG’s Sandoz unit and Momenta, on the grounds that it would deny the public an important treatment.
Sanofi-Aventis has expressed concerns that the US Food and Drug Administration has failed to follow procedures and failed to ensure that the generic, which was approved in July, has the same active ingredient as Lovenox.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData